Risk of rejection By combining the two cells and delivering them into patients receiving a transplant, their immune system will learn to recognize the donor's cells, which are present throughout their new face, making their immune cells less likely to attack the face  If the (immune system) can recognize more cells as 'self' the patient will need less anti-rejection drugs, says Siemionow, whose experimental therapy is hoped to enter clinical trials in a few years and when it does, may make face transplants more acceptable to critics 